| Dr Maxfield D Richardson, DO | |
|
200 State Ave, Faribault, MN 55021-6339 | |
| (507) 334-6451 | |
| Not Available |
| Full Name | Dr Maxfield D Richardson |
|---|---|
| Gender | Male |
| Speciality | General Surgery |
| Experience | 12 Years |
| Location | 200 State Ave, Faribault, Minnesota |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1023379955 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208600000X | Surgery | 5101020014 (Michigan) | Secondary |
| 208600000X | Surgery | 62260 (Minnesota) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Mercy Hospital | Coon rapids, MN | Hospital |
| District One Hospital | Faribault, MN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Allina Health System | 4587573613 | 3071 |
News Archive
An international team of researchers has found that adding a humanized monoclonal antibody called daclizumab to standard treatment reduces the number of new or enlarged brain lesions in patients with relapsing multiple sclerosis. This new study was published online Feb. 16, 2010, and in the March edition of the Lancet Neurology.
RXi Pharmaceuticals Corporation, a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted and immunotherapy technologies, today announced the completion of its previously announced acquisition of Apthera, Inc.
Based on a strategy to deliver a broad range of assays for use on the Celerus Wave® System, Jason Lusk, Vice President of Sales and Marketing, today announced the availability of Wave Direct Immunofluorescence (IF).
Humana Inc. announced today that it has completed its previously announced acquisition of Arcadian Management Services, an Oakland, Calif.-based company that, through its affiliates, operates Medicare Advantage HMO plans.
› Verified 1 days ago
| Entity Name | Range Regional Health Services |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1669569265 PECOS PAC ID: 8022920024 Enrollment ID: O20031110000095 |
News Archive
An international team of researchers has found that adding a humanized monoclonal antibody called daclizumab to standard treatment reduces the number of new or enlarged brain lesions in patients with relapsing multiple sclerosis. This new study was published online Feb. 16, 2010, and in the March edition of the Lancet Neurology.
RXi Pharmaceuticals Corporation, a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted and immunotherapy technologies, today announced the completion of its previously announced acquisition of Apthera, Inc.
Based on a strategy to deliver a broad range of assays for use on the Celerus Wave® System, Jason Lusk, Vice President of Sales and Marketing, today announced the availability of Wave Direct Immunofluorescence (IF).
Humana Inc. announced today that it has completed its previously announced acquisition of Arcadian Management Services, an Oakland, Calif.-based company that, through its affiliates, operates Medicare Advantage HMO plans.
› Verified 1 days ago
| Entity Name | Allina Health System |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1295272342 PECOS PAC ID: 4587573613 Enrollment ID: O20040319000460 |
News Archive
An international team of researchers has found that adding a humanized monoclonal antibody called daclizumab to standard treatment reduces the number of new or enlarged brain lesions in patients with relapsing multiple sclerosis. This new study was published online Feb. 16, 2010, and in the March edition of the Lancet Neurology.
RXi Pharmaceuticals Corporation, a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted and immunotherapy technologies, today announced the completion of its previously announced acquisition of Apthera, Inc.
Based on a strategy to deliver a broad range of assays for use on the Celerus Wave® System, Jason Lusk, Vice President of Sales and Marketing, today announced the availability of Wave Direct Immunofluorescence (IF).
Humana Inc. announced today that it has completed its previously announced acquisition of Arcadian Management Services, an Oakland, Calif.-based company that, through its affiliates, operates Medicare Advantage HMO plans.
› Verified 1 days ago
| Entity Name | Allina Health System |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1457657249 PECOS PAC ID: 4587573613 Enrollment ID: O20221213001713 |
News Archive
An international team of researchers has found that adding a humanized monoclonal antibody called daclizumab to standard treatment reduces the number of new or enlarged brain lesions in patients with relapsing multiple sclerosis. This new study was published online Feb. 16, 2010, and in the March edition of the Lancet Neurology.
RXi Pharmaceuticals Corporation, a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted and immunotherapy technologies, today announced the completion of its previously announced acquisition of Apthera, Inc.
Based on a strategy to deliver a broad range of assays for use on the Celerus Wave® System, Jason Lusk, Vice President of Sales and Marketing, today announced the availability of Wave Direct Immunofluorescence (IF).
Humana Inc. announced today that it has completed its previously announced acquisition of Arcadian Management Services, an Oakland, Calif.-based company that, through its affiliates, operates Medicare Advantage HMO plans.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Maxfield D Richardson, DO 200 State Ave, Faribault, MN 55021-6339 Ph: (507) 334-6451 | Dr Maxfield D Richardson, DO 200 State Ave, Faribault, MN 55021-6339 Ph: (507) 334-6451 |
News Archive
An international team of researchers has found that adding a humanized monoclonal antibody called daclizumab to standard treatment reduces the number of new or enlarged brain lesions in patients with relapsing multiple sclerosis. This new study was published online Feb. 16, 2010, and in the March edition of the Lancet Neurology.
RXi Pharmaceuticals Corporation, a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted and immunotherapy technologies, today announced the completion of its previously announced acquisition of Apthera, Inc.
Based on a strategy to deliver a broad range of assays for use on the Celerus Wave® System, Jason Lusk, Vice President of Sales and Marketing, today announced the availability of Wave Direct Immunofluorescence (IF).
Humana Inc. announced today that it has completed its previously announced acquisition of Arcadian Management Services, an Oakland, Calif.-based company that, through its affiliates, operates Medicare Advantage HMO plans.
› Verified 1 days ago
Roderick Ralph Byron, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 924 1st St Ne, Faribault, MN 55021 Phone: 507-333-3300 Fax: 507-333-3214 | |
Henry M Busch Jr., MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 100 State Ave, Faribault, MN 55021 Phone: 507-334-3921 Fax: 507-332-5297 | |
Dr. Julie Ann Zachwieja, D.O., B.S. Surgery Medicare: Medicare Enrolled Practice Location: 100 State Ave, Faribault, MN 55021 Phone: 507-334-3921 |